PartitionBio

Senior Marketing Manager  |  Oct 2025 — Present

Building the brand, go-to-market strategy, and commercial presence for BubbleFect — a novel lipid-free cell delivery platform built on biomolecular condensate technology, developed by PartitionBio.

PartitionBio is an early-stage biotech company founded by Niall Armes. When I joined, BubbleFect existed as a scientific breakthrough with no brand, no market presence, and no go-to-market strategy. Working closely with the founder and the science team, my job was to change that.

The challenge was twofold: BubbleFect is a genuinely novel technology in a market used to established players, and the customer testing cycle is over 8 months — meaning results take time, and every touchpoint needs to count.

ELRIG Drug Discovery 2025 - Innovation Award

PartitionBio exhibited at ELRIG Drug Discovery in October 2025 as part of the Innovation Avenue programme. I led the event strategy, stand design, and outreach. We won the Innovation Award — a significant milestone for a first-year company in a competitive field.

Beyond the award, the event and the LinkedIn outreach that followed it directly generated new paid projects with global pharma organisations.

Graphic Design

I developed the full BubbleFect visual identity from scratch — including the brand look and feel, colour palette, typography, and design language. The brief was to create something that felt scientific and credible, but also bold and distinctive in a market full of conservative, blue-toned competitors.

All marketing materials for PartitionBio are designed by me — from the scientific imagery used across the website and social media, to event materials, product datasheets, and presentation decks.

Web Design

I designed and built the PartitionBio and BubbleFect websites, creating a product-led structure that clearly communicates the technology, the evidence, and the path to getting started. The site needed to speak to both research scientists and procurement teams at large pharmaceutical organisations — two audiences with very different needs.

www.partitionbio.co.uk

Marketing

I developed and executed the full go-to-market strategy for BubbleFect, including the Alpha and Beta testing programme that became the core engine for early customer acquisition. The programme was designed to get the product into the hands of serious researchers at credible institutions while generating the data and feedback needed to refine the commercial offer.

  • 90 organisations recruited into the Alpha and Beta programme within 6 months.

  • 12 global pharmaceutical companies included in the programme.

  • 3 global pharma organisations converted to paying customers, despite an 8+ month testing cycle.

  • 5 further global pharma partnership conversations currently in active commercial discussion.